We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
Read MoreHide Full Article
Aerie Pharmaceuticals, Inc. announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone intravitreal implant). The company will now initiate studies for AR-1105 for the treatment of macular edema due to retinal vein occlusion (RVO). Aerie plans to begin a phase II study later in the first quarter of 2019.
Shares of Aerie have declined 26% in the past year compared with the industry’s decline of 19.6%.
AR-1105 is a bio-erodible implant that is designed to release the steroid dexamethasone over a six-month sustained period. It is commonly administered through intravitreal injection. The benefits of AR-1105 versus other steroid products are its six-month duration of efficacy, improved administration owing to a smaller needle size and a better safety profile due to lower peak drug levels.
AR-1105 is the first IND stage candidate in Aerie’s retina pipeline. The company also plans to file an IND for its second retina product for the treatment of wet age-related macular degeneration and diabetic macular edema.
The advancements of these candidates will make Aerie reach its goal of being the next major ophthalmic pharmaceutical company.
We remind investors that another company Regeneron’s (REGN - Free Report) drug Eylea, which is co-developed by HealthCare unit of Bayer AG (BAYRY - Free Report) , is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Merck’s earnings per share estimates have increased from $4.28 to $4.33 for 2018 and from $4.65 to $4.69 for 2019 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 3.96%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
Aerie Pharmaceuticals, Inc. announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone intravitreal implant). The company will now initiate studies for AR-1105 for the treatment of macular edema due to retinal vein occlusion (RVO). Aerie plans to begin a phase II study later in the first quarter of 2019.
Shares of Aerie have declined 26% in the past year compared with the industry’s decline of 19.6%.
AR-1105 is a bio-erodible implant that is designed to release the steroid dexamethasone over a six-month sustained period. It is commonly administered through intravitreal injection. The benefits of AR-1105 versus other steroid products are its six-month duration of efficacy, improved administration owing to a smaller needle size and a better safety profile due to lower peak drug levels.
AR-1105 is the first IND stage candidate in Aerie’s retina pipeline. The company also plans to file an IND for its second retina product for the treatment of wet age-related macular degeneration and diabetic macular edema.
The advancements of these candidates will make Aerie reach its goal of being the next major ophthalmic pharmaceutical company.
We remind investors that another company Regeneron’s (REGN - Free Report) drug Eylea, which is co-developed by HealthCare unit of Bayer AG (BAYRY - Free Report) , is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Aerie Pharmaceuticals, Inc. Price
Aerie Pharmaceuticals, Inc. Price | Aerie Pharmaceuticals, Inc. Quote
Zacks Rank and A Stock to Consider
Aerie currently carries a Zacks Rank #4 (Sell).
A better-ranked stock from the same space is Merck & Co., Inc. (MRK - Free Report) , which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merck’s earnings per share estimates have increased from $4.28 to $4.33 for 2018 and from $4.65 to $4.69 for 2019 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 3.96%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>